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Purpose of the study
To assess the feasibility of a rescue ETV-containing cART
regimen in naïve patients with primary NNRTI resistance
mutations or after first NNRTI failure, using the latest
resistance score presented.
Methods
A set of 17 mutations (V90I, A98G, L100I, K101E/H/P,
V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S, M230L)
were found associated with ETV resistance in the Phase III
DUET-1 and DUET-2 trials. Recently, a different score was
assigned to each mutation (i.e. Y181C/I have the highest
score: 3). An overall score of ≤4 was associated with
reduced response and a score between 2.5–3.5 with inter-
mediate response (reference). ETV resistance was calcu-
lated from a large database of patients undergoing
genotypic resistance test.
Results
Overall, 241 ARV-naïve patients and 311 failing a first
NNRTI regimen (EFV = 189, NVP = 122) were analyzed.
Among naïve patients, 14 (5.8%) harbored ≤1 major
NNRTI resistance mutation but only in one patient
(0.4%) a ≤4 score, and in five patients (2.1%) a score
between 2.5–3.5 were detected.
Among failing patients, two-thirds harbored major
NNRTI mutations (about half had K103N). In contrast, a
≤4 score was found in 5.8% of patients, with similar pro-
portion in EFV- and NVP-treated patients (5.8% vs. 5.7%),
though among NVP patients a score between 2.5–3.5 was
more frequently found (28.7% vs. 20.1%).
The probability of developing a ≤4 score was 0.0% during
the first 3 months of NNRTI failure and 3.1% between 3–
6 months (2.6% in EFV vs. 3.9% in NVP failure). Subse-
quently, during EFV failure, the probability of developing
a ≤4 score increased between 6–12 months to 20.0% (par-
ticularly between 9–12 months: 23.5%) and during NVP
failure, between 9–12 months to 9.1%.
At adjusted logistic regression, remaining in NNRTI fail-
ure between 6–12 months was the only factor associated
to developing a ≤4 ETV score (OR: 22.0, 95& CI: 2.65–
182.89, p = 0.004).
Conclusion
The presence of mutations predictive of full or intermedi-
ate ETV resistance is uncommon among naïve patients,
thus, in almost all cases, ETV use may be allowed. The
detection of ETV-resistance is also infrequent in patients
failing a NNRTI regimen because usually they develop the
K103N mutation, that alone or in combination does not
affect ETV sensitivity. Our data also suggest that a quick
withdrawal of a failing NNRTI regimen, possibly in the
first 3 months of failure, can maintain ETV sensitivity,
thus preserving a treatment option.
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